Related Experiment Video
Updated: Oct 2, 2026

One-day Workflow Scheme for Bacterial Pathogen Detection and Antimicrobial Resistance Testing from Blood Cultures
Published on: July 9, 2012
Five-day cefdinir course vs. ten-day cefprozil course for treatment of acute otitis media
S L Block1, J Kratzer, M A Nemeth
1Kentucky Pediatric Research, Bardstown, USA.
Insights
A 5-day course of cefdinir is as effective and well-tolerated as a 10-day course of cefprozil for treating pediatric acute otitis media (AOM). This shorter cefdinir regimen offers a comparable treatment option for AOM in children.
Area of Science:
- Pediatric infectious diseases
- Clinical pharmacology
- Antimicrobial stewardship
Background:
- Acute otitis media (AOM) is a common childhood infection.
- Antibiotic therapy is the mainstay of AOM treatment.
- Optimizing antibiotic duration is crucial for efficacy and reducing resistance.
Purpose of the Study:
- To compare the clinical efficacy and tolerability of a 5-day cefdinir regimen versus a 10-day cefprozil regimen for pediatric AOM.
- To evaluate cefdinir as a shorter-course alternative for AOM treatment.
Main Methods:
- A comparative, investigator-blinded, multicenter trial was conducted.
- Children aged 6 months to 12 years with AOM were enrolled.
- Patients received either 5-day cefdinir or 10-day cefprozil.
Main Results:
- Clinical cure rates were similar: 80% for cefdinir and 82.5% for cefprozil.
- Adverse reactions were comparable between the two groups.
- Diarrhea was reported slightly more in the cefdinir group (7.8%) than cefprozil (4.2%).
Conclusions:
- A 5-day cefdinir regimen is clinically effective and well-tolerated for nonrefractory pediatric AOM.
- This shorter cefdinir course provides a viable alternative to longer cefprozil treatment.
- Findings support the use of shorter antibiotic courses when efficacy is maintained.
Objective:
To compare the clinical efficacy of a 5-day cefdinir course with a 10-day cefprozil course in the treatment of pediatric acute otitis media (AOM).
Design:
Comparative, investigator-blinded multicenter trial.
Setting:
Primary care, ambulatory.
Patients:
Children ages 6 months through 12 years with clinical symptoms and tympanic membrane signs of AOM, plus tympanometric-confirmed middle ear effusion in at least 1 ear. Of the 435 patients enrolled in the study, 373 were evaluable.
Intervention:
Patients received cefdinir 14 mg/ kg/day divided twice a day for 5 days or cefprozil 30 mg/kg/day divided twice a day for 10 days.
Main Outcome Measures:
Clinical resolution of tympanic membrane signs and symptoms of AOM determined at end of therapy on Study Days 9 to 11.
Results:
The clinical cure rate at end of therapy was 80% (152 of 190) for cefdinir-treated patients and 82.5% (151 of 183) for cefprozil-treated patients (95% confidence interval, 10.43% to 5.4%). Diarrhea and overall adverse reactions, respectively, occurred in 7.8 and 13% of cefdinir-treated patients and in 4.2 and 12% of cefprozil-treated patients.
Conclusions:
A short course 5-day regimen of cefdinir was as clinically effective and well-tolerated as a 10-day regimen of cefprozil in the treatment of nonrefractory AOM.
More Related Videos
06:51Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
Published on: December 10, 2016
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
Related Concept Videos
Acute Pharyngitis
Acute pharyngitis is the inflammation of the back of the throat (pharynx), commonly resulting in a sore throat. It is a frequently encountered condition that prompts individuals to seek medical advice.
Classification
Acute pharyngitis can be categorized based on its underlying cause:
Tonsillitis II: Management
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
Acute Pyelonephritis II: Diagnostic Studies and Management
Mechanism of Antibiotic Resistance in MRSA